Senseonics Holdings, Inc. (SENS)
NYSEAMERICAN: SENS · IEX Real-Time Price · USD
0.463
-0.024 (-5.03%)
May 1, 2024, 4:00 PM EDT - Market closed
Senseonics Holdings Revenue
In the year 2023, Senseonics Holdings had annual revenue of $22.39M with 36.62% growth. Revenue in the quarter ending December 31, 2023 was $8.03M with 44.14% year-over-year growth.
Revenue (ttm)
$22.39M
Revenue Growth
+36.62%
P/S Ratio
10.96
Revenue / Employee
$169,621
Employees
132
Market Cap
245.43M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 22.39M | 6.00M | 36.62% |
Dec 31, 2022 | 16.39M | 2.71M | 19.85% |
Dec 31, 2021 | 13.68M | 8.73M | 176.32% |
Dec 31, 2020 | 4.95M | -16.35M | -76.77% |
Dec 31, 2019 | 21.30M | 2.39M | 12.63% |
Dec 31, 2018 | 18.91M | 12.54M | 196.77% |
Dec 31, 2017 | 6.37M | 6.04M | 1,819.58% |
Dec 31, 2016 | 332.00K | 294.00K | 773.68% |
Dec 31, 2015 | 38.00K | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AngioDynamics | 324.01M |
Coherus BioSciences | 257.24M |
2seventy bio | 100.39M |
Poseida Therapeutics | 64.70M |
AVITA Medical | 51.57M |
Ovid Therapeutics | 391.70K |
SENS News
- 1 day ago - Senseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time - Business Wire
- 1 day ago - Eversense® CGM System Receives iCGM Designation by the US FDA - Business Wire
- 7 weeks ago - SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS - PRNewsWire
- 7 weeks ago - Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes - Business Wire
- 2 months ago - Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference - Business Wire
- 2 months ago - Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results - Business Wire
- 2 months ago - Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time - Business Wire
- 2 months ago - Medicare Coverage Significantly Expanded for the Eversense E3 CGM System - Business Wire